Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | NFATC1 | O95644 | 3/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 1/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25028296 | 0.86 | HTR2A (0.64) | HTR6DYRK1AGSK3BNFATC1HTR2A | |
| SCHEMBL3221770 | 0.86 | DYRK1A (0.51) | HTR6DYRK1AGSK3BNFATC1GPR84 | |
| SCHEMBL25030294 | 0.83 | HTR6 (0.61) | HTR6DYRK1AGSK3BNFATC1HTR2A | |
| SCHEMBL3899319 | 0.83 | HTR6 (0.76) | HTR6DYRK1AGSK3BNFATC1HTR2A | |
| SCHEMBL31036068 | 0.83 | HTR6 (0.76) | HTR6DYRK1AGSK3BNFATC1HTR2A | |
| SCHEMBL3924792 | 0.83 | GSK3B (0.53) | HTR6DYRK1AGSK3BNFATC1GPR84 | |
| SCHEMBL17341178 | 0.82 | HTR6 (0.44) | HTR6DYRK1AGSK3BNFATC1GPR84 | |
| SCHEMBL25029930 | 0.82 | HTR2A (0.62) | HTR6DYRK1AGSK3BNFATC1GPR84 | |
| SCHEMBL25030259 | 0.82 | HTR6 (0.78) | HTR6HTR2AHTR1A | |
| SCHEMBL14021920 | 0.82 | HTR6 (0.49) | HTR6DYRK1AGSK3BNFATC1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708323-B2 | Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170137425-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137425-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA6, CHRNA5 | HTR6 93/4885DYRK1A 3018/4885GSK3B 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.